- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02280434
Phase 1 Study Accessing the Safety and Tolerability of CBP-307
November 1, 2016 updated by: Suzhou Connect Biopharmaceuticals, Ltd.
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CBP-307 Following Oral Single and Multiple Escalating Dose Administration
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CBP-307 following oral single and multiple escalating dose administration in healthy subjects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CBP-307 following oral single and multiple escalating dose administration in healthy subjects.
The study will have two parts: Part 1 will assess 5 dose levels of the drug in single dosing; and Part 2 will evaluate 3 dose levels in 28-day repeat dosing.
The effect of food will also be evaluated in a single dosing study.
Study Type
Interventional
Enrollment (Anticipated)
64
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Nucleus Network
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Informed consent must be obtained in writing for all subjects at enrollment into the study
- Healthy male subjects age between 18 and 55 years, inclusive
- Body mass index (BMI) between 19 and 30 kg/m2, inclusive
- No clinically significant findings in the medical history and physical examination, especially with regard to the liver and gastrointestinal systems
- No clinically significant laboratory values and urinalysis, unless the investigator considers any abnormality to be clinically irrelevant
- Normal ECG, blood pressure, and heart rate, unless the investigator considers any abnormality to be clinically irrelevant
- Resting heart rate ≥ 55 bpm
Exclusion Criteria:
- Family history of premature CHD (Coronary Heart Disease)
- Any condition requiring the regular use of any medication
- Exposure to prescription medications or to drugs known to interfere with metabolism of drugs within 30 days prior to screening
- Exposure to any other medication, including over-the counter medications, herbal remedies and vitamins 14 days prior to randomization (except paracetamol (see Section 5.2 Prior and concomitant treatments)
- Participation in another study with any investigational drug in the 2 months preceding the study
- Treatment in the previous 3 months with any drug known to have a well defined potential for toxicity to a major organ
- Positive urine cotinine result at screening
- Be in the exclusion period of any previous study with investigational drugs
- Symptoms of a clinically significant illness in the 3 months before the study
- Presence or sequelae of gastrointestinal, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs
- Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease
- Hemorrhoids or anal diseases with regular or recent presence of blood in feces
- History of significant allergic disease (e.g. medications) and acute phase of allergic rhinitis in the previous 2 weeks before randomization or any food allergy
- Blood or plasma donation of more than 500 ml during the previous 2 month before randomization and/or more than 50 ml in the 2 weeks prior to screening
- Subjects at risk for tuberculosis (TB), specifically subjects with: Current clinical, radiographic or laboratory evidence of active TB; history of active TB unless there is documentation that the prior anti-TB treatment was appropriate in duration and type;latent TB which has not been successfully treated; a positive quantiFERON® test at screening or within 6 months prior to Day 1
- Known positive test for HIV
- Known positive test for hepatitis B (antigens HBs, antibody HBc) or C, unless caused by immunization
- History of shingles or recurrent episodes of HSV1 or HSV2 infections
- Current evidence of drug abuse or history of drug abuse within one year before randomization
- History of alcohol abuse or active alcoholism as defined in Appendix A Definition of alcohol abuse
- Mental condition rendering the subject incapable to understand the nature, scope, and possible consequences of the study
- Adults under guardianship and people with restriction of freedom by administrative or legal decisions
- Unlikely to comply with the clinical study protocol; e.g. uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study
- Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
- Systolic blood pressure less than 95 mmHg or greater than 140 mmHg, or diastolic blood pressure less than or equal to 50 mmHg or greater than or equal to 95 mmHg.
- Subjects with resting heart rate less than 55 beats per minute or greater than 90 beats per minute.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: CBP-307
Participants will receive a single dose or once daily dose of CBP-307 for 28 days.
|
|
Placebo Comparator: Placebo
Participants will receive a single dose or once daily dose of matching placebo for 28 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: up to 6 weeks
|
Safety measurements will include vital signs, hematology, blood chemistry, blood pressure and other readouts.
|
up to 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma Concentrations of Study Drug Over Time and Maximal Plasma Concentration (Cmax)
Time Frame: Up to 6 weeks
|
Up to 6 weeks
|
Elimination Half-live (T1/2) of Study Drug
Time Frame: Up to 6 weeks
|
Up to 6 weeks
|
Exposure to Study Drug Measured as Area Under the Curve (AUC)
Time Frame: Up to 6 weeks
|
Up to 6 weeks
|
Effect of Study Drug on Blood Lymphocyte Counts
Time Frame: Up to 6 weeks
|
Up to 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jason Lickliter, MD, PhD, FRACP, Nucleus Network
- Study Director: Zheng Wei, PhD, Suzhou Connect Biopharmaceuticals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2014
Primary Completion (Actual)
August 1, 2015
Study Completion (Actual)
August 1, 2015
Study Registration Dates
First Submitted
October 20, 2014
First Submitted That Met QC Criteria
October 29, 2014
First Posted (Estimate)
October 31, 2014
Study Record Updates
Last Update Posted (Estimate)
November 3, 2016
Last Update Submitted That Met QC Criteria
November 1, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CBP-307AU001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autoimmune Diseases
-
SanofiRecruitingHealthy Volunteers | Autoimmune DisorderUnited States
-
National Eye Institute (NEI)Completed
-
The Eye Center and The Eye Foundation for Research...CompletedAutoimmune Polyglandular Syndrome Type I | Autoimmune Keratitis
-
Sinocelltech Ltd.Not yet recruiting
-
TakedaCompletedAutoimmune DiseaseUnited Kingdom
-
Ziv HospitalUnknownAutoimmune DiseaseIsrael
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedAutoimmune DisordersUnited States
-
Muğla Sıtkı Koçman UniversityCompletedMultiple Sclerosis | Telerehabilitation | Autoimmune Disorder | Exercise ProgramTurkey
-
Fundación Pública Andaluza Progreso y SaludKarolinska Institutet; Eli Lilly and Company; Medical University of Vienna; Sanofi and other collaboratorsCompletedSystemic Autoimmune DiseasesFrance, Belgium, Germany, Italy, Spain, Switzerland
-
Ruijin HospitalRecruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States